Buprenorphine SR Avian Dosing

David Sanchez, Migallon Guzman, LV, MS, Dipl. ECZM

The information contained in this study is provided for educational and informational purposes only, and should not be construed as suggesting, implying, establishing or making claims in any manner or respect regarding the safety, efficacy or therapeutic benefit of any of Wedgewood's compounded drug preparations. Any such claims can only be made with respect to drugs that have been tested in accordance with studies and labels approved by the United States Food and Drug Administration. Wedgewood is a compounding pharmacy whose preparations, by law, are not required to go through FDA's new drug approval process and, therefore, have not been tested for safety and efficacy. Wedgewood does not and should not be construed to make any safety, efficacy or other health claims about its compounded drug preparations and any implication to the contrary is specifically disavowed.

The information contained in this study is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a practitioner with any questions you may have regarding a medical condition or the medications used to treat it.

Important Update:

In order to remain compliant with the most current regulatory guidelines, we have updated the labeling on our SR formulations from Buprenorphine and Meloxicam SR to Buprenorphine and Meloxicam in Polymer. As of April 1, 2024, SR preparations mentioned in the attached study are now labeled as in Polymer, with no changes to the formulation of the medication(s).



David Sanchez-Migallon Guzman, LV, MS, Dipl. ECZM (Avian), Dipl. ACZM Avian and Exotic Pet Medicine and Surgery School of Veterinary Medicine University of California Davis One Shields Avenue 2108 Tupper Hall Davis, California 95616 Cell phone: 608 556 4248 Email: guzman@ucdavis.edu